Daniel Carcillo

Here, sharing an article I contributed to: "Rescheduling of Cannabis: What the Experts Think" on CBD Oracle. 🚀 This compilation joins thoughts from a dozen industry experts, around what moving cannabis from Schedule I to Schedule III could mean for everyone involved – from users and researchers to businesses and policymakers. I had the chance to share my thoughts alongside a strong group of other experts in the field. We covered a lot of ground, from legal implications to scientific research and economic impacts. It’s a comprehensive look at a topic that’s more relevant than ever. Check it out the summary here: https://lnkd.in/es5E745R Or the full interviews here: https://lnkd.in/euGCHbiQ This discussion isn't going anywhere... no matter who gets elected, cannabis will be front and center of human culture from now on... Certainly so, if there's anything I have to say about it! 😉 Let’s keep the conversation going! 🌿💬

13

5 Comments

My Take on the US proposed rescheduling of cannabis The proposal to reschedule cannabis from Schedule I to Schedule III, is a very interesting paper to read. The DEA, it seems, has applied a different method of analyzing the use, effects and danger parameters of cannabis versus other drugs with high potential for abuse listed in Schedule I, and has reversed its 2016 negative opinion. It has done so based, at the end, on the contradictory fact, that because multiple States have ignored the FDA and DEA, and have set up a medical cannabis regime – this in itself has allowed the DEA to collect a lot more data on cannabis, ultimately reaching the conclusion that cannabis has comparably less potential for abuse. If we put aside Biden's wish to get more people to vote for him, this change in policy is an example of how, sometimes, grassroots movements do change federal policy. I do want to pose a question for Americans reading this post: Will rescheduling prompt doctors to write more prescriptions, knowing that they are not breaking federal law (as Schedule I drugs are not to be prescribed), although such prescriptions are for products that are not FDA approved? https://lnkd.in/d2R42zbd

12

Brand loyalty doesn't exist in cannabis yet. No c@nn@bis brands are pulling the cultural & psychological levers to drive customers to develop a long-lasting connection. Rather, the crux of all c@nn@bis loyalty programs is receiving points/rewards/discounts, which is transaction-based instead of relationship-based. So customers have little to no emotional tie with a brand. As more and more adult-use markets come online, customers are quick to leave a retailer when something closer becomes available to them. Convenience is king. In addition customers can be easily swayed to a different brand with promotions and discounts. Plus, there's not a lot of clear differentiation among retailers, either in products available or customer experience. Agree? Disagree?

68

64 Comments